找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller (Professor and Head of Department) Book 20101st edition Springer-Ver

[復(fù)制鏈接]
樓主: monster
11#
發(fā)表于 2025-3-23 12:57:21 | 只看該作者
12#
發(fā)表于 2025-3-23 15:45:35 | 只看該作者
Current concepts of pharmacogenetics, pharmacogenomics, and the “druggable” genomelity can be translated into clinical practice. According to the current intriguing concepts of pharmacogenetics and pharmacogenomics, genetic information of individuals will be used to avoid “trial and error” scenarios during medication. Based on evidence from genomic testing, medicine is expected t
13#
發(fā)表于 2025-3-23 20:56:23 | 只看該作者
Biomarkerstifying biological markers as indicators for an underlying disease is an elementary concept in medicine. Since the beginning of the medical skill of healing, signs and symptoms have been interpreted by medical doctors and guided diagnosis and treatment of their patients. With the emergence of the bi
14#
發(fā)表于 2025-3-24 01:00:03 | 只看該作者
15#
發(fā)表于 2025-3-24 06:24:44 | 只看該作者
16#
發(fā)表于 2025-3-24 06:36:49 | 只看該作者
17#
發(fā)表于 2025-3-24 14:22:58 | 只看該作者
Safe Filler Injection Techniquesronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
18#
發(fā)表于 2025-3-24 17:56:37 | 只看該作者
Epidemiology and bio statisticsronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
19#
發(fā)表于 2025-3-24 22:53:03 | 只看該作者
Andrew M. Dearden,Michael D. Harrison, (b) clinically, by administering appropriate drug therapy to patients and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.
20#
發(fā)表于 2025-3-25 00:38:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 22:02
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
芜湖市| 石阡县| 如皋市| 黑山县| 枝江市| 孝昌县| 尚志市| 赫章县| 平顺县| 东辽县| 交城县| 莲花县| 康平县| 岱山县| 涞源县| 高碑店市| 文安县| 山东省| 会昌县| 万盛区| 桃江县| 仪陇县| 庆元县| 隆尧县| 红河县| 仙桃市| 台山市| 中阳县| 龙南县| 荥阳市| 成武县| 礼泉县| 醴陵市| 金门县| 拜城县| 安多县| 济宁市| 高清| 鹤峰县| 娄底市| 台江县|